Lesson plan
B7-33
B7-33 is a synthetic 26-amino acid peptide with the sequence VIKLSGRELVRAQIAISGMSTWSKRSL or Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu. It is an N-terminal truncated, C-terminal extended fragment from the B chain of human relaxin-2, and has similar anti-fibrotic effects to the full length peptide. It has been researched for conditions where excess fibrosis plays a role, such as cardiac fibrosis and pulmonary fibrosis.
Article summary
B7-33 is a synthetic 26-amino acid peptide with the sequence VIKLSGRELVRAQIAISGMSTWSKRSL or Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu. It is an N-terminal truncated, C-terminal extended fragment from the B chain of human relaxin-2, and has similar anti-fibrotic effects to the full length peptide. It has been researched for conditions where excess fibrosis plays a role, such as cardiac fibrosis and pulmonary fibrosis.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.